Pressure BioSciences (PBIO) investor relations material

Operational updates and relocation

• Relocation to a new facility with 90% manufacturing labs has improved operational efficiency and reduced costs by consolidating R&D and manufacturing, increasing space by 20% while lowering lease expenses by 20-30%.

• The move caused significant delays, including late regulatory approvals and lab setup, impacting financial filings and operations, but the company is now fully functional and ready for business.

• The new facility enables future growth and in-house manufacturing, shifting from a virtual to a manufacturing-focused company.

Financial and compliance status

• The 2023 10-K annual report was filed late due to relocation delays, with a commitment to avoid future late filings; the Q filing is targeted for June 30.

• Management acknowledges the inconvenience to stakeholders and is working to restore compliance and maintain it going forward.

Core business and technology focus

• Pressure Cycling Technology (PCT) and BaroFold remain important, with ongoing sales and service, but focus has shifted to UltraShear technology due to its market potential.

• UltraShear enables precise, stable nano-emulsions, significantly improving absorption of oil-based actives, as demonstrated in preclinical studies with CBD and THC.

• UltraShear's applications span pharmaceuticals, nutraceuticals, cosmetics, agrochemicals, and food and beverage, targeting multi-billion dollar markets.